Atossa Therapeutics, Inc. (ATOS)
Stock Price:
$1.57 USD
0.00 (0.00%)
Updated November 25, 4:00 PM EST - Market closed
After-hours: $1.61 +0.04 (2.55%) Nov 25, 7:35 PM
Key Info
| Market Cap |
16.47M |
| Revenue (ttm) |
n/a |
| Net Income (ttm) |
-12.96M |
| Shares Out |
10.49M |
| EPS (ttm) |
-1.38 |
| PE Ratio |
n/a |
| Forward PE |
n/a |
| Dividend |
n/a |
| Dividend Yield |
n/a |
Stock Quote
| Trading Day |
November 25 |
| Last Price |
$1.57 |
| Previous Close |
$1.57 |
| Change ($) |
0.00 |
| Change (%) |
0.00% |
| Day's Open |
1.57 |
| Day's Range |
1.52 - 1.61 |
| Day's Volume |
141,515 |
| 52-Week Range |
0.76 - 5.08 |
More Stats
| Market Cap |
16.47M |
| Enterprise Value |
7.29M |
| Earnings Date (est) |
Apr 1, 2021 |
| Ex-Dividend Date |
n/a |
| Shares Outstanding |
10.49M |
| Float |
10.46M |
| EPS (basic) |
-1.35 |
| EPS (diluted) |
-1.38 |
| FCF / Share |
-1.07 |
| Dividend |
n/a |
| Dividend Yield |
n/a |
| Earnings Yield |
n/a |
| FCF Yield |
n/a |
| Payout Ratio |
n/a |
| Shares Short |
200,075 |
| Short Ratio |
1.79 |
| Short % of Float |
1.91% |
| Beta |
2.59 |
| PE Ratio |
n/a |
| Forward PE |
n/a |
| P/FCF Ratio |
n/a |
| PS Ratio |
n/a |
| PB Ratio |
1.87 |
| Revenue |
n/a |
| Operating Income |
-13.01M |
| Net Income |
-12.96M |
| Free Cash Flow |
-10.86M |
| Net Cash |
9.18M |
| Net Cash / Share |
0.88 |
| Gross Margin |
n/a |
| Operating Margin |
n/a |
| Profit Margin |
n/a |
| FCF Margin |
n/a |
| ROA |
-57.96% |
| ROE |
-104.16% |
| ROIC |
-1,563.00% |
Stats based on trailing-twelve-month (ttm) numbers.
Analyst Forecasts
Analyst Ratings (2)
| Buy |
2 |
| Overweight |
0 |
| Hold |
0 |
| Underweight |
0 |
| Sell |
0 |
Price Target
$6.25*
(298.09% upside)
Low
5.00
Current: $1.57
High
7.50
Target: 6.25
*Average 12-month price target from 2 stock analysts.
Financial Performance
Financial numbers in millions USD.
Financial Overview
| Year | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 |
|---|
| Revenue | - | - | - | - | - | 0.04 | 0.63 | 0.48 | - |
| Revenue Growth | - | - | - | - | -95.62% | -93.65% | 31.28% | 32022.8% | - |
| Gross Profit | - | - | - | - | -0.13 | 0.04 | 0.14 | 0.42 | -0.10 |
| Operating Income | -17.27 | -11.43 | -7.65 | -7.97 | -12.76 | -12.17 | -10.78 | -5.07 | -3.43 |
| Net Income | -17.24 | -11.40 | -8.12 | -6.37 | -15.76 | -14.66 | -10.78 | -5.08 | -3.44 |
| Shares Outstanding | 8.50 | 4.16 | 0.97 | 0.25 | 0.16 | 0.13 | 0.09 | 0.07 | 0.05 |
| Earnings Per Share | -2.03 | -5.50 | -10.97 | -25.92 | -99.72 | -109.80 | -126.00 | -73.80 | -68.40 |
| Operating Cash Flow | -9.13 | -8.96 | -6.59 | -5.37 | -13.95 | -10.56 | -8.83 | -3.90 | -3.49 |
| Capital Expenditures | -0.01 | -0.11 | - | -0.01 | -0.13 | 0.16 | -0.24 | -0.10 | -0.14 |
| Free Cash Flow | -9.14 | -9.07 | -6.59 | -5.38 | -14.08 | -10.40 | -9.07 | -4.00 | -3.63 |
| Cash & Equivalents | 12.69 | 10.49 | 7.27 | 3.08 | 3.99 | 8.50 | 6.34 | 1.73 | 2.91 |
| Total Debt | 0.05 | - | - | - | - | - | 0.02 | - | 1.01 |
| Net Cash / Debt | 12.64 | 10.49 | 7.27 | 3.08 | 3.99 | 8.50 | 6.33 | 1.73 | 1.91 |
| Assets | 14.49 | 11.72 | 8.16 | 4.14 | 6.24 | 11.76 | 12.01 | 6.83 | 3.07 |
| Liabilities | 1.33 | 2.92 | 1.23 | 1.05 | 2.50 | 2.27 | 1.41 | 1.65 | 1.51 |
| Book Value | 13.16 | 8.81 | 6.94 | 3.10 | 3.74 | 9.50 | 10.60 | 5.18 | 1.56 |
Numbers in millions USD, except per-share numbers.
Company Details
| Full Name |
Atossa Therapeutics, Inc. |
| Country |
United States |
| Employees |
4 |
| CEO |
Steven C. Quay |
Stock Information
| Ticker Symbol |
ATOS |
| Stock Exchange |
NASDAQ |
| Sector |
Healthcare |
| Industry |
Biotechnology |
| Unique Identifier |
NASDAQ: ATOS |
| IPO Date |
November 8, 2012 |
Description
Atossa Therapeutics develops and markets medical devices, laboratory tests, and therapeutics to address breast health conditions in the United States. The company's lead program is the development of Endoxifen, an active metabolite of tamoxifen which is in Phase II studies to treat and prevent breast cancer. It is also developing intraductal microcatheter technology to target the delivery of therapies, including fulvestrant, immunotherapies, and Chimeric Antigen Receptor T-cell therapies, directly to the site of breast cancer. The company was formerly known as Atossa Genetics Inc. and changed its name to Atossa Therapeutics, Inc. in January 2020. Atossa Therapeutics, Inc. was founded in 2009 and is headquartered in Seattle, Washington.